ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma
Tajima, K.; Hirama, M.; Shiomi, K.; Ishiwata, T.; Yoshioka, M.; Iwase, A.; Iwakami, S.; Yamazaki, M.; Toba, M.; Tobino, K.; Sugano, K.; Ichikawa, M.; Hagiwara, Y.; Takahashi, K.; Hino, O.
Anticancer Research 28(6b): 3933-3936
2008
ISSN/ISBN: 0250-7005 PMID: 19192652 Document Number: 618883
It has been recently reported that soluble mesothelin-related protein (SMRP), serum mesothelin, and osteopontin (OPN) are considered as relevant biomarkers for the diagnosis of mesothelioma. The aim of this study was to investigate whether serum N-ERC/mesothelin, an NH3-terminal fragment of mesothelin, and plasma OPN reflect chemotherapeutic effect in patients with mesothelioma. Serum N-ERC/mesothelin and plasma osteopontin were determined with a sandwich enzyme-linked immunosorbent assay (ELISA) system. The average N-ERC ratio, determined by dividing the N-ERC levels following chemotherapy by those prior to chemotherapy, in the partial response (PR) group was significantly lower than that of the stable disease (SD)/progressive disease (PD) group. In contrast, the average OPN ratio, determined by dividing the OPN levels following chemotherapy by those prior to chemotherapy, in the PR group was not statistically different from that of the SD/PD group. N-ERC/mesothelin is considered as relevant in monitoring chemotherapeutic response in patients with mesothelioma.